Ed Arce

The expected start of combination clinical trials has H.C. Wainwright bullish on shares of Arbutus Biopharma Corp. (NASDAQ: ABUS). The Arbutus Analyst: Ed Arce raffirmed a Buy rating on shares of Arbutus Biopharma Corp. with a $10 price target.  The Arbutus Takeaways: On Tuesday, Arbutus...

Shares of nano-cap Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH), which have never really recovered from a steep sell-off triggered by an adverse clinical readout in late 2015, are surging Thursday after a second bidder emerged. Two-way Race The Watertown, Massachusetts-based company, which has a...

DURECT Corporation (NASDAQ: DRRX) has had a rough few months since the failure of a Phase 3 trial for its formerly leading drug candidate. Days after reporting top- and bottom-line quarterly beats, the biotech received support in the form of an upgrade from H.C. Wainwright.  The Rating...

Following Akebia Therapeutics Inc's (NASDAQ: AKBA) announcement of an expanded agreement with Otsuka (OTC: OTSKY) to develop and commercialize Vadadustat in Europe, China and Other Territories, HC Wainwright said in a note that the European partnership provides strong economics, removing any...

On March 28, Galectin Therapeutics Inc (NASDAQ: GALT) provided an update on the progress of its lead program, the Phase 2b trial of GR-MD-02 in Non-Alcoholic Steato-Hepatitis patients with cirrhosis (NASH-CX). Citing a “more positive view of the therapeutic potential of the mechanism of...

Ocera Therapeutics Inc (NASDAQ: OCRX)'s lead drug, OCR-002, has “the potential to become the gold standard” for the treatment as well as prevention of overt hepatic encephalopathy in patients with liver cirrhosis, H.C. Wainwright’s Ed Arce said in a report. He initiated coverage...

HC Wainwright has started coverage of The Medicines Company (NASDAQ: MDCO) with a Buy rating and $57 price target on the back of Phase 3-ready inclisiran (PCSK9si). Key Catalyst: Inclisiran Inclisiran is an RNAi therapeutic that inhibits synthesis of PCSK9 directly in the liver for potent and...

On September 27, Galectin Therapeutics Inc (NASDAQ: GALT) announced its Phase 2 NASH-FX trial had failed to achieve both the primary and secondary endpoints. H.C. Wainwright’s Ed Arce downgraded the rating on the company to Neutral while lowering the price target from $8.00 to $1.50....

Galenica AG has announced a definitive agreement to acquire Relypsa Inc (NASDAQ: RLYP) for $32 per share in cash. H.C. Wainwright’s Ed Arce commented that this puts an end to “at least nine months of near constant take out speculation.” He downgraded the rating on the company...

On May 16, Relypsa Inc (NASDAQ: RLYP) released the launch metrics for Veltassa for the month of April. H.C. Wainwright’s Ed Arce reiterated a Buy rating on the company, with a price target of $32. ‘New Starts’ Down Arce mentioned that “New Starts” were marginally down...